HSA 2027 Conference Programme

Asia's health economy is expanding across far more than hospitals and medicines. Population ageing, chronic disease, rising consumer expectations, new financing models and digital infrastructure are redirecting demand across diagnostics, medical technology, pharmaceuticals, insurance, care services and prevention. Yet growth is uneven: regulation, purchasing power, health-system capacity and reimbursement differ sharply across markets. This presentation offers a disciplined view of where demand is likely to deepen, which business models can scale and where apparent growth may not translate into a viable opportunity.

Malaysia's health reform agenda is moving from diagnosis to implementation, with changes in private healthcare financing, insurance design, digital infrastructure, data interoperability, public-private delivery and value-based decisionmaking. This panel translates policy into operational consequences: affordability and access; hospital pricing and margins; insurance and takaful product design; data, claims and coding; procurement; and investment confidence.

By 2050, one in four people in Asia and the Pacific is expected to be aged 60 or older. This presentation maps the emerging silver economy across independent and assisted living, home healthcare, rehabilitation, AgeTech, remote monitoring, long-term care financing, mobility, prevention and professional caregiving, and examines where capital is moving and which needs remain poorly served.

Healthcare capital is still available, but it is concentrating in fewer, larger and better-evidenced opportunities. This panel examines venture and growth equity, strategic corporate investment, infrastructure capital and development finance, and what investors will back across digital health, diagnostics, medical technology, care delivery and evidence-based wellness in 2027.

Artificial intelligence is moving from demonstration into clinical, operational and research settings, but adoption will be determined by evidence and governance rather than novelty. This presentation identifies the applications most likely to create value over the next three years, and confronts the conditions required for safe scale.

Malaysia can provide a credible base for regional growth, but there is no single route into either Malaysia or ASEAN. This presentation shows how regulatory sequencing should connect with commercial strategy, when a distributor should be appointed, and which market-entry decisions are difficult to reverse.

Regulatory approval grants permission to enter a market; it does not create demand or a purchase order. This panel examines the next commercial gate: what hospitals, pharmacy channels and regional distributors require before they will list, procure, represent or scale a product.

Precision medicine uses clinical, molecular, genomic and other health data to guide prevention, diagnosis and treatment for the individual. This presentation explores how biomarker-led diagnosis, companion diagnostics, advanced imaging, liquid biopsy and targeted therapies are enabling earlier detection and more specific treatment pathways.

Robotic assistance, advanced imaging, navigation, interventional radiology and minimally invasive techniques are changing how clinicians plan and perform complex procedures. This panel examines evidence, patient selection and measurable outcomes alongside the practical requirements of implementation.

Malaysia's health system is entering a defining phase. This closing keynote sets out Malaysia's priorities for the next phase of health transformation, from stronger primary care and workforce capability to digital integration, innovation and cross-sector collaboration.